Darunavir Krka is a brand name for Darunavir. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of…
Verbatim from this product's EMA label. Tap a section to expand.
Therapy should be initiated by a healthcare provider experienced in the management of HIV infection. After therapy with darunavir has been initiated, patients should be advised not to alter the dose, dose form or discontinue therapy without discussing with their healthcare provider.
3 The interaction profile of darunavir depends on whether ritonavir is used as pharmacokinetic enhancer. 5). Posology Darunavir must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
The Summary of Product Characteristics of ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir. This medicinal product is only available as film coated tablets and is thus not suitable for patients who are unable to swallow intact tablets, for example young children.
For use in these patients, more suitable formulations containing darunavir should be checked for their availability. ART-naïve adult patients The recommended dose regimen is 800 mg once daily taken with ritonavir 100 mg once daily taken with food.
Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen. 1) a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used. Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.
- In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. See the Summary of Product Characteristics for Darunavir Krka 600 mg tablets.
* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V ART-naïve paediatric patients (3 to 17 years of age and weighing at least 40 kg) The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.
1) a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used. Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen. The dose of other pharmacokinetic enhancer to be used with darunavir in children less than 12 years of age has not been established.
3% of subjects experienced at least one adverse reaction. 3 weeks. The most frequent adverse reactions reported in clinical studies and as spontaneous reports are diarrhoea, nausea, rash, headache and vomiting. The most frequent serious reactions are acute renal failure, myocardial infarction, immune reconstitution inflammatory syndrome, thrombocytopenia, osteonecrosis, diarrhoea, hepatitis and pyrexia.
In the 96 week analysis, the safety profile of darunavir/ritonavir 800/100 mg once daily in treatment- naïve subjects was similar to that seen with darunavir/ritonavir 600/100 mg twice daily in treatment- experienced subjects except for nausea which was observed more frequently in treatment-naïve subjects.
This was driven by mild intensity nausea. 5 weeks. 5% of subjects experienced at least one adverse reaction. 4 weeks. The most frequent adverse reactions reported were diarrhoea (28%), nausea (23%), and rash (16%). Serious adverse reactions are diabetes mellitus, (drug) hypersensitivity, immune reconstitution inflammatory syndrome, rash and vomiting.
24 For information on cobicistat, consult the cobicistat Summary of Product Characteristics. Tabulated list of adverse reactions Adverse reactions are listed by system organ class (SOC) and frequency category. Within each frequency category, adverse reactions are presented in order of decreasing seriousness.
Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) and not known (frequency cannot be estimated from the available data). Table 2.
Adverse reactions observed with darunavir/ritonavir in clinical studies and post-marketing MedDRA system organ class Frequency category Adverse reaction Infections and infestations uncommon herpes simplex Blood and lymphatic system disorders uncommon rare thrombocytopenia, neutropenia, anaemia, leukopenia increased eosinophil count Immune system disorders uncommon immune reconstitution inflammatory syndrome, (drug) hypersensitivity Endocrine disorders uncommon hypothyroidism, increased blood thyroid stimulating hormone Metabolism and nutrition disorders common uncommon diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase Psychiatric disorders common insomnia uncommon depression, disorientation, anxiety, sleep disorder, abnormal dreams, nightmare, decreased libido rare confusional state, altered mood, restlessness Nervous system disorders common headache, peripheral neuropathy, dizziness uncommon lethargy, paraesthesia, hypoaesthesia, dysgeusia, disturbance in attention, memory impairment, somnolence rare syncope, convulsion, ageusia, sleep phase rhythm disturbance Eye disorders uncommon conjunctival hyperaemia, dry eye rare visual disturbance Ear and labyrinth disorders 25 uncommon vertigo Cardiac disorders uncommon myocardial infarction, angina pectoris, prolonged electrocardiogram QT, tachycardia rare acute myocardial infarction, sinus bradycardia, palpitations Vascular disorders uncommon hypertension, flushing Respiratory, thoracic and mediastinal disorders uncommon dyspnoea, cough, epistaxis, throat irritation rare rhinorrhoea Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence uncommon pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia rare stomatitis, haematemesis, cheilitis, dry lip, coated tongue Hepatobiliary disorders common increased alanine aminotransferase uncommon hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase Skin and subcutaneous tissue disorders common rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus uncommon angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation rare DRESS, Stevens-Johnson syndrome, erythema multiforme, dermatitis, seborrhoeic dermatitis, skin lesion, xeroderma not known toxic epidermal necrolysis, acute generalised exanthematous pustulosis Musculoskeletal and connective tissue disorders uncommon myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase rare musculoskeletal stiffness, arthritis, joint stiffness Renal and urinary disorders uncommon acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, proteinuria, 26 bilirubinuria, dysuria, nocturia, pollakiuria rare decreased creatinine renal clearance rare crystal nephropathy§ Reproductive system and breast disorders uncommon erectile dysfunction, gynaecomastia General disorders and administration site conditions common asthenia, fatigue uncommon pyrexia, chest pain, peripheral oedema, malaise, feeling hot, irritability, pain […]
Regular assessment of virological response is advised. In the setting of lack or loss of virological response, resistance testing should be performed. 2). The Summary of Product Characteristics of cobicistat or ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir.
2 did not significantly affect darunavir concentrations. It is not recommended to alter the dose of cobicistat or ritonavir. Darunavir binds predominantly to 1-acid glycoprotein. This protein binding is concentration- dependent indicative for saturation of binding.
5). 2). Combinations with optimised background regimen (OBRs) other than ≥ 2 NRTIs have not been studied in this population. 1). 3). Pregnancy Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
2). 2). Cobicistat levels decrease and may not provide sufficient boosting. The substantial reduction in darunavir exposure may result in virological failure and an increased risk of mother to child transmission of HIV infection. 6). Darunavir given with low dose ritonavir may be considered as an alternative.
2). 4% of patients. 1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported. Darunavir should be discontinued immediately if signs or symptoms of severe skin reactions develop.
These can include, but are not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia. 8). Darunavir contains a sulphonamide moiety.
Darunavir should be used with caution in patients with a known sulphonamide allergy. g. acute hepatitis, cytolytic hepatitis) has been reported with darunavir. 5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir.
1. Patients with severe (Child-Pugh Class C) hepatic impairment. 5). 5). The strong CYP3A inducers rifampicin and herbal preparations containing St John’s wort (Hypericum perforatum). 5). Applicable to darunavir boosted with cobicistat, not when boosted with ritonavir: Darunavir boosted with cobicistat is more sensitive for CYP3A induction than darunavir boosted with ritonavir.
Concomitant use with strong CYP3A inducers is contraindicated, since these may reduce the exposure to cobicistat and darunavir leading to loss of therapeutic effect. g. 5). Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the co- administered medicinal product.
Therefore, concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (applies to darunavir boosted with either ritonavir or cobicistat).
g. 5).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Darunavir in European Union.
Know a brand we are missing in European Union? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
- In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is described in the Summary of Product Characteristics for Darunavir Krka 600 mg tablets. * DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V Advice on missed doses If a once daily dose of darunavir and/or ritonavir is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of darunavir and ritonavir with food as soon as possible.
If this is noticed later than 12 hours after the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule. This guidance is based on the half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 24 hours.
4 If a patient vomits within 4 hours of taking the medicinal product, another dose of darunavir with ritonavir should be taken with food as soon as possible. If a patient vomits more than 4 hours after taking the medicinal product, the patient does not need to take another dose of darunavir with ritonavir until the next regularly scheduled time.
2). Hepatic impairment Darunavir is metabolised by the hepatic system. No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, darunavir should be used with caution in these patients.
No pharmacokinetic data are available in patients with severe hepatic impairment. Severe hepatic impairment could result in an increase of darunavir exposure and a worsening of its safety profile. 2). 2). 1). For dose recommendations in children see the Summary of Product Characteristics for Darunavir Krka 600 mg tablets.
Pregnancy and postpartum No dose adjustment is required for darunavir/ritonavir during pregnancy and postpartum. 2). 2). Therefore, therapy with darunavir/cobicistat should not be initiated […]
Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir used in combination with cobicistat or low dose ritonavir and patients should be monitored during treatment. Increased aspartate aminotransferase/alanine aminotransferase (AST/ALT) monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre- treatment elevations of transaminases, especially during the first several months of darunavir used in combination with cobicistat or low dose ritonavir treatment.
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using darunavir used in combination with cobicistat or low dose ritonavir, interruption or discontinuation of treatment should be considered promptly.
Patients with coexisting conditions Hepatic impairment The safety and efficacy of darunavir have not been established in patients with severe underlying liver disorders and darunavir is therefore contraindicated in […]